Extracellular Vesicle Core

细胞外囊泡核心

• 批准号: 10630390
• 负责人: Sicheng Wen
• 金额: $ 21.32万
• 依托单位: RHODE ISLAND HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-01 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10630390
• 关键词: Acute Myelocytic Leukemia; Aging; Alzheimer' s Disease; Alzheimer’s disease biomarker; Area; Award; Basic Science; Binding; Biological Markers; Biology; Bioreactors; Blood; Body Fluids; Bone Marrow; Brain; Cell secretion; Centers of Research Excellence; Cerebrospinal Fluid; Chronic; Clinical; Code; Collaborations; Colon; Communities; Consultations; Core Facility; Coupled; DNA; Data Collection; Disease; Effectiveness; Environment; Experimental Designs; Feasibility Studies; Foundations; Funding; Grant; HIV; Harvest; Heart; Hospitals; Immune; Immune checkpoint inhibitor; Immunoassay; Immunooncology; Industry; Infant; Institution; Laboratories; Large Intestine; Lasers; Lipids; Liver; Lung; Malignant neoplasm of lung; Mediating; Medical Oncologist; Medical center; Membrane; Messenger RNA; Methods; MicroRNAs; Molecular; Myocardial Ischemia; Neurodegenerative Disorders; Patients; Phase; Phenotype; Plasma; Play; Preparation; Proteins; Protocols documentation; Pulmonary Hypertension; Research; Research Personnel; Research Support; Rhode Island; Robot; Role; Saliva; Services; Surface; Suspensions; System; Techniques; Time; Tissues; Translational Research; Translations; United States National Institutes of Health; Universities; Untranslated RNA; Woman; checkpoint therapy; clinically significant; disorder prevention; experience; experimental study; extracellular vesicles; fiber cell; instrumentation; intercellular communication; liquid biopsy; nanoparticle; novel therapeutic intervention; prevent; stem cells; transcriptome sequencing

Project Summary/Abstract The COBRE Center for Stem Cells and Aging at Rhode Island Hospital established the unique Extracellular Vesicle Core in July 2019. The aims of the Extracellular Vesicle Core are: 1) To provide the research community at Rhode Island Hospital and outside of Rhode Island Hospital with expertise to support research in the field of Extracellular Vesicle (EV). 2) To assist with EV experimental design, data collection, analysis, and storage, as well as preparation for NIH, industry, or foundation grant submissions. 3) To enhance the collaboration and translational research environment in the Rhode Island research community. 4) To become a financially independent Core facility after Phase 3 of the COBRE. The Extracellular Vesicle Core instrumentation mainly consists of two Thermo WX-40 ultracentrifuges, a Tangenx LHV tangential flow system, Applied Biosystems ViiA™ 7 Real-Time PCR System with Twister robot, a Malvern NanoSight NS 500 with two lasers (405nm and 488nm), and a Fiber Cell Systems duet bioreactor. The Extracellular Vesicle Core is a state-of-the-art facility that will continue to enhance collaboration and translational research in the hospital and university communities. In collaboration with clinical doctors from Rhode Island Hospital, our Core has made significant contributions to investigating the clinical significance of EVs as non-invasive “liquid biopsy” biomarkers for tracking the effectiveness of disease therapy. This resulted in a $1.4 million grant in 2020 from Bristol Myers Squibb, where approximately $350,000 was awarded to Dr. Quesenberry’s lab specifically for the Extracellular Vesicle Core. Dr. John Reagan obtained $860,000 from Pfizer for his study of Acute Myeloid Leukemia, where EV-related research was executed through the Extracellular Vesicle Core. Dr. Jill Kreiling got her NIH R01 in 2022, for the study of the feasibility of using extracellular vesicles in saliva as biomarkers for Alzheimer’s disease where $60,000 per year was committed to the Extracellular Vesicle Core in the next five years. In the last three years, the Extracellular Vesicle Core has serviced 18 projects for 22 investigators from 15 different academic departments at five Institutions (Brown University, Rhode Island Hospital, Women and Infants Hospital, the University of Rhode Island, and Providence VA Medical Center). These projects demonstrate that the Extracellular Vesicle Core will continue to play a crucial role in supporting regional projects and facilitating the basic research and the translation of novel therapeutic approaches to the treatment and prevention of disease.

项目总结/摘要 罗得岛医院的COBRE干细胞和衰老中心建立了独特的细胞外 2019年7月的囊泡核心。细胞外囊泡核心的目的是：1）为研究社区提供 在罗得岛医院和罗得岛医院外，拥有支持以下领域研究的专业知识： 细胞外囊泡（EV）。2)协助EV实验设计、数据收集、分析和存储， 以及为NIH、行业或基金会拨款申请做准备。3)加强合作， 在罗得岛研究界的转化研究环境。4)成为一个经济上 COBRE第三阶段后的独立核心设施。细胞外囊泡核心器械主要 由两台Thermo WX-40超离心泵、一台Tangenx LHV切向流系统、Applied Biosystems 配备Twister机器人的ViiA™ 7实时PCR系统，一台配备两个激光器（405 nm和100 nm）的马尔文NanoSight NS 500 488 nm）和Fiber Cell Systems duet生物反应器。细胞外囊泡核心是一个最先进的设施， 将继续加强医院和大学社区的合作和转化研究。在 与来自罗得岛医院的临床医生合作，我们的核心做出了重大贡献， 研究EV作为非侵入性“液体活检”生物标志物用于追踪 疾病治疗的有效性。这导致布里斯托迈尔斯施贵宝在2020年提供了140万美元的赠款， Quesenberry博士的实验室获得了大约35万美元的奖金，专门用于细胞外囊泡核心。 博士约翰·里根从辉瑞公司获得了86万美元，用于他对急性髓系白血病的研究， 研究是通过细胞外囊泡核心进行的。Jill Kreiling博士在2022年获得了NIH R 01， 使用唾液中的细胞外囊泡作为阿尔茨海默病生物标志物的可行性研究， 在接下来的五年里，每年将有60，000美元用于细胞外囊泡核心。在过去的三年里， 细胞外囊泡核心已经为来自15个不同学术机构的22名研究人员提供了18个项目的服务。 五个机构的部门（布朗大学，罗得岛医院，妇女和婴儿医院， 罗得岛大学和普罗维登斯VA医学中心）。这些项目表明， 细胞外囊泡核心将继续在支持区域项目和促进 基础研究和将新的治疗方法转化为治疗和预防疾病。